Massachusetts Financial Services Co. MA Has $1.04 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS)

Massachusetts Financial Services Co. MA decreased its holdings in Arcus Biosciences, Inc. (NYSE:RCUSFree Report) by 3.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 58,126 shares of the company’s stock after selling 2,227 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.08% of Arcus Biosciences worth $1,043,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of RCUS. MetLife Investment Management LLC lifted its holdings in Arcus Biosciences by 57.4% in the first quarter. MetLife Investment Management LLC now owns 25,039 shares of the company’s stock valued at $790,000 after buying an additional 9,127 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Arcus Biosciences by 77.0% during the first quarter. Dimensional Fund Advisors LP now owns 437,969 shares of the company’s stock valued at $13,826,000 after purchasing an additional 190,527 shares during the period. Vanguard Group Inc. raised its holdings in shares of Arcus Biosciences by 2.5% during the first quarter. Vanguard Group Inc. now owns 3,512,114 shares of the company’s stock valued at $110,843,000 after purchasing an additional 85,778 shares during the period. Ergoteles LLC acquired a new position in shares of Arcus Biosciences during the first quarter valued at about $1,261,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Arcus Biosciences during the first quarter valued at about $76,000. Institutional investors own 74.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald dropped their price objective on shares of Arcus Biosciences from $46.00 to $36.00 and set an “overweight” rating on the stock in a report on Wednesday, November 8th. Wedbush decreased their target price on shares of Arcus Biosciences from $36.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, January 30th. Mizuho decreased their target price on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, January 30th. Finally, Morgan Stanley decreased their target price on shares of Arcus Biosciences from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $41.25.

View Our Latest Stock Report on Arcus Biosciences

Arcus Biosciences Stock Up 4.1 %

Shares of RCUS stock opened at $16.47 on Tuesday. Arcus Biosciences, Inc. has a 52-week low of $12.95 and a 52-week high of $25.47. The company has a 50-day simple moving average of $16.91 and a two-hundred day simple moving average of $17.37.

Insider Activity

In related news, major shareholder Gilead Sciences, Inc. bought 15,238,095 shares of Arcus Biosciences stock in a transaction dated Monday, January 29th. The stock was purchased at an average cost of $21.00 per share, with a total value of $319,999,995.00. Following the transaction, the insider now directly owns 30,061,124 shares of the company’s stock, valued at $631,283,604. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder Gilead Sciences, Inc. bought 15,238,095 shares of Arcus Biosciences stock in a transaction dated Monday, January 29th. The stock was purchased at an average cost of $21.00 per share, with a total value of $319,999,995.00. Following the transaction, the insider now directly owns 30,061,124 shares of the company’s stock, valued at $631,283,604. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Jennifer Jarrett sold 21,521 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $17.76, for a total transaction of $382,212.96. Following the transaction, the chief operating officer now directly owns 258,878 shares of the company’s stock, valued at $4,597,673.28. The disclosure for this sale can be found here. Insiders sold 30,500 shares of company stock valued at $562,421 in the last three months. Company insiders own 13.80% of the company’s stock.

Arcus Biosciences Company Profile

(Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Featured Articles

Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc. (NYSE:RCUSFree Report).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.